Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00369473 | Long-Term Assessment of Safety and Physical Function With AMG 108 in RA | PHASE2 | COMPLETED | 690 | — | — | Sep 1, 2006 | Jun 1, 2008 | Dec 13, 2016 | - | — |
| NCT00293826 | A Multiple Dose Study to Evaluate Subcutaneous AMG 108 in Subjects With Rheumatoid Arthritis | PHASE2 | COMPLETED | 813 | — | — | Mar 1, 2006 | Feb 1, 2008 | Mar 5, 2010 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | 350 |
| 2 | EXPERIMENTAL | 350 |
| 3 | EXPERIMENTAL | 196 subjects |
| 4 | PLACEBO_COMPARATOR | 196 subjects |
| Name | Type | Description |
|---|---|---|
| AMG 108 | DRUG | 125 mg via SC (subcutaneous) injection every 4 weeks |
| Placebo | DRUG | Placebo via SC (subcutaneous) injection every 4 weeks |
Inclusion Criteria: * Only subjects eligible for and completing 24 weeks of study 20050168 will be permitted to enroll. Exclusion Criteria: * Subjects not eligible for or not completing 24 weeks of study 20050168 will be excluded.